编号：2024-014 证券代码：688520 证券简称：神州细胞 北京神州细胞生物技术集团股份公司 投资者关系活动记录表 | --- | --- | --- | |---------------------|-----------------------------------|-------------------------------------------------------------------------------------------------------------| | | | | | | | 特定对象调研 分析师会议 | | 投资者关系 | | 媒体采访 业绩说明会 | | 活动类别 | 新闻发布会 路演活动 | | | | 现场参观 其他 | | | 时间 | 2024 年 11 月 14 日 | | | 地点 | | 上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/ ） | | 接待人员 | | 谢良志（董事长、总经理）；唐黎明（董事、副总经理、董事会秘书）；马洁 （董事、财务总监）；王晓川（独立董事） | | 投资者关系 活动 ...

证券代码：688520 证券简称：神州细胞 公告编号：2024-030 北京神州细胞生物技术集团股份公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 线上文字互动平台：上海证券交易所上证路演中心（https://roadshow.ss einfo.com/） 投资者可于 2024 年 11 月 7 日（星期四）至 11 月 13 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sinocelltech.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 北京神州细胞生物技术集团股份公司（以下简称"公司"）已于 2024 年 10 月 29 日在上海证券交易所网站（www.sse.com.cn）披露了公司 2024 年第三季度 报告。为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财 务状况，公司计划于 2024 年 11 月 14 日 11:00-12:00 举行 2024 ...

《科创板日报》11月5日讯（记者 徐红）随着国家医保局打击欺诈骗保行动的不断推进，其波及面持续 扩大。继阿斯利康之后，又有一家药企陷入骗保风波。 近期有媒体报道称，因在核心产品安佳因®销售过程中涉嫌骗保，神州细胞（688520.SH）多位医药代 表和地区经理已被警方带走调查。 4日，《科创板日报》记者就此事联系到神州细胞，但公司否认因涉嫌骗保被查，并回应称，"截至目 前，尚未收到有关部门针对公司的调查通知"。 虽然事情尚无定论，但此次神州细胞卷入"骗保"漩涡引发市场关注，一个很重要的原因在于，涉事的安 佳因®（重组人凝血因子VIII）是目前神州细胞的支柱产品，也是神州细胞最主要的营收来源。 严监管之下，整个医药产业势必将进一步提升合规管理水平。而对于神州细胞来说，化解公司过度依赖 单一产品的风险，或许也会变得更加紧迫。 ▌贡献超九成营收，神州细胞单品打天下 神州细胞主营业务是单克隆抗体、重组蛋白和疫苗等生物制品的研发和产业化。截至目前，公司已有四 个产品获批上市，包括重组八因子产品安佳因®和CD20单抗安平希®。另外，两个生物类似药阿达木单 抗产品安佳润®和贝伐珠单抗产品安贝珠® 也已经于2023年6月先后获 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][11]. Core Insights - The company achieved a revenue of 19.37 billion RMB in the first three quarters of 2024, representing a year-on-year growth of 40.44%. The net profit attributable to the parent company was 1.50 billion RMB, with a non-recurring net profit of 4.62 billion RMB, marking a significant turnaround from losses in the same period of 2023 [2][3]. - The company is expected to achieve its first annual profit, driven by the increased market share of its product Anjain® and continued innovation in its product offerings [3]. - The company has a robust pipeline with multiple products approved and ongoing clinical trials, including an RSV vaccine recently approved for clinical use [3][4]. Revenue and Profit Forecast - The revenue forecast for the company is set at 27 billion RMB for 2024, 36 billion RMB for 2025, and 45 billion RMB for 2026. However, the net profit estimates have been revised downwards to 2.1 billion RMB, 4.2 billion RMB, and 7.3 billion RMB for the respective years [4][7]. R&D Investment - The company invested 2.12 billion RMB in R&D in Q3 2024, totaling 6.72 billion RMB for the first three quarters, which is 34.68% of its revenue [3]. Market Position and Product Development - The company has successfully developed multiple antibody products with stringent DNA residue quality standards, significantly outperforming similar foreign products [3]. - The company has a total of four products approved, with three vaccine varieties included in emergency use by the government, and is actively pursuing additional clinical trials for new products [3]. Financial Metrics - The company reported a diluted earnings per share of 0.473 RMB for 2024, with projections of 0.953 RMB for 2025 and 1.643 RMB for 2026 [7]. - The return on equity (ROE) is projected to be 50.78% for 2025 and 46.68% for 2026, indicating strong profitability potential [7]. Stock Performance - The current market price of the company's stock is 40.79 RMB, with a historical trend showing consistent "Buy" ratings from analysts [5][11].

Financial Performance - The company's operating revenue for Q3 2024 was ¥632,311,576.28, representing a 10.70% increase year-over-year[2]. - The net profit attributable to shareholders for the year-to-date period reached ¥149,954,058.54, with a significant increase of 40.44% compared to the same period last year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥122,114,485.39, a remarkable increase of 287.87% year-over-year[2]. - Total operating revenue for the first three quarters of 2024 reached CNY 1,936,981,204.36, a 40.3% increase from CNY 1,379,251,634.17 in the same period of 2023[14]. - Operating profit for the first three quarters of 2024 was CNY 530,132,183.15, compared to CNY 58,121,539.53 in the previous year, indicating a significant improvement[14]. - Net profit for the first three quarters of 2024 was CNY 150,412,418.63, a turnaround from a net loss of CNY 220,383,751.08 in the same period of 2023[15]. - The total comprehensive income for the first three quarters of 2024 was CNY 150,443,258.67, compared to a loss of CNY 220,451,425.46 in the same period of 2023[15]. Research and Development - Research and development (R&D) expenses totaled ¥215,198,108.17 for Q3 2024, a decrease of 32.11% compared to the same period last year[3]. - R&D expenses accounted for 34.03% of operating revenue, a decrease of 21.46 percentage points year-over-year[3]. - Research and development expenses for the first three quarters of 2024 totaled CNY 671,785,468.55, down from CNY 806,115,168.18 in the previous year, reflecting a 16.6% decrease[14]. Assets and Liabilities - The total assets of the company as of the end of Q3 2024 were ¥3,155,544,473.63, reflecting a growth of 16.08% compared to the end of the previous year[3]. - Total current assets increased to CNY 1,404,065,834.23 as of September 30, 2024, up from CNY 1,060,347,468.42 at the end of 2023, representing a growth of approximately 32.4%[10]. - The company's total equity attributable to shareholders improved to CNY -127,980,957.92 from CNY -599,461,618.33 in the previous year, showing a positive trend[12]. - The company's total assets increased to CNY 3,155,544,473.63 from CNY 2,718,536,171.39 year-over-year, indicating growth in asset base[12]. - Total liabilities decreased slightly to CNY 3,289,419,850.23 from CNY 3,324,350,645.59 year-over-year[12]. Cash Flow - The company reported a net cash flow from operating activities of ¥189,690,262.61 for the year-to-date period, indicating an increase due to higher sales revenue[5]. - The cash inflow from operating activities for the first three quarters of 2024 was CNY 1,865,018,609.44, an increase of 33.4% compared to CNY 1,399,193,356.76 in the same period of 2023[17]. - The net cash flow from operating activities was CNY 189,690,262.61, a significant improvement from a net outflow of CNY 373,677,900.53 in the previous year[17]. - The cash inflow from investment activities totaled CNY 752,090,314.65, down from CNY 1,036,648,222.34 in the first three quarters of 2023[18]. - The net cash flow from investment activities was negative at CNY -302,400,963.34, compared to CNY -412,354,804.44 in the same period last year[18]. - The cash inflow from financing activities was CNY 1,634,794,236.21, an increase from CNY 1,358,027,023.53 in the previous year[18]. - The net cash flow from financing activities was CNY 159,750,367.26, a decrease from CNY 224,270,913.28 in the same period of 2023[18]. Strategic Focus - The company is focusing on new product development and market expansion strategies to enhance growth prospects in the upcoming quarters[9]. - The company is actively exploring potential mergers and acquisitions to strengthen its market position and expand its operational capabilities[9]. Shareholder and Financing Activities - The company has not reported any significant changes in shareholder structure or major financing activities during the reporting period[8].

证券代码：688520 证券简称：神州细胞 公告编号：2024-029 北京神州细胞生物技术集团股份公司 自愿披露关于控股子公司重组呼吸道合胞病毒疫苗 SCTV02 获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 一、产品基本情况 1. 产品名称：SCTV02 注射液 2. 受理号：CXSL2400481 3. 申请事项：药物临床试验 4. 申请人：神州细胞工程有限公司 审批结论：根据《中华人民共和国药品管理法》、《中华人民共和国疫苗管理 法》及有关规定，经审查，申请人提交的 SCTV02 注射液符合药品注册的有关要 求，同意开展临床试验。 二、产品其他相关情况 呼吸道合胞病毒（RSV）可以引起全年龄段人群的呼吸道感染，常见症状包 括咳嗽、咳痰、喘息和发热，是全球引起 5 岁以下儿童、老年人及免疫功能低下 人群急性下呼吸道感染的重要病原体，目前尚无特异性抗病毒治疗药物。SCTV02 注射液是公司以差异化竞争优势为目标自主开发的预防 RSV 感染所致呼吸道疾 病的重组蛋白疫苗 ...

编号：2024-013 证券代码：688520 证券简称：神州细胞 北京神州细胞生物技术集团股份公司 投资者关系活动记录表 | --- | --- | --- | |------------------------------|------------------------------------|-------------------------------------------------------------------------------------------------------------| | | | | | | | 特定对象调研 分析师会议 | | 投资者关系 | | 媒体采访 业绩说明会 | | 活动类别 | 新闻发布会 路演活动 | | | | 现场参观 其他 | | | 时间 | 2024 年 9 月 18 日 | | | 地点 | | 上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/ ） | | 接待人员 | | 谢良志（董事长、总经理）；唐黎明（董事、副总经理、董事会秘书）；马洁 （董事、财务总监）；王晓川（独立董事） | | ...

Financial Performance - In the first half of 2024, the company reported a revenue of approximately 1.305 billion RMB, representing a year-on-year growth of 61.45% [2] - The net profit attributable to shareholders was approximately 126 million RMB, marking a turnaround from a loss [2] - Research and development investment for the first half of 2024 was about 476 million RMB, accounting for 36.48% of total revenue [2] Product Development - The company has commercialized one recombinant protein drug (Anjain®) and three antibody drugs (Anpingxi®, Anjairun®, Anbeizhu®), which are approved for treating hemophilia, autoimmune diseases, and malignant tumors [3] - The 4-valent COVID-19 vaccine (AnuoNeng® 4) has received emergency use authorization [3] - Ongoing clinical trials include PD-1 monoclonal antibody SCT-I10A for head and neck squamous cell carcinoma and liver cancer, and the 14-valent HPV vaccine SCT1000, which has completed Phase III clinical studies [3] Market Potential and Challenges - Currently, there are 20,000 to 30,000 registered hemophilia patients in China, with a treatment penetration rate of less than 20% [4] - The average annual treatment cost for these patients is estimated at 5,000 to 6,000 IU, significantly lower than the international recommended dosage of 25 IU/kg every two days [4] - The overall treatment level for hemophilia patients in China is considerably below international standards, leading to increased social burdens [4] Strategic Initiatives - The company aims to mitigate the impact of price reductions from centralized procurement of factor VIII products by leveraging its competitive advantages in quality, supply, and pricing [5] - Plans for international expansion of Anjain® are underway, with partnerships established in several Belt and Road countries, aiming for commercialization starting in 2025 [5] - The company is focused on achieving positive net assets through increased revenue and equity financing, with a plan to raise up to 800 million RMB through perpetual bond financing [6]

证券代码：688520 证券简称：神州细胞 北京神州细胞生物技术集团股份公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |---------------------|------------------------------------|------------------------------------------|----------------|--------------------|------------------------------| | | | | | 编号： | 2024-012 | | | | 特定对象调研 分析师会议 | | | | | 投资者关系 | | 媒体采访 业绩说明会 | | | | | 活动类别 | 新闻发布会 路演活动 | | | | | | | 现场参观 其他 | | | | | | 时间 | 2024 年 9 月 13 日 | | | | | | 参与单位 | 09:00-10:30 11:00-12:00 德邦证券 | 鹏华基金、国泰君安证券 | | | | | 地点 | 公司会议室 | | | | ...

中信证券股份有限公司 关于北京神州细胞生物技术集团股份公司 2024 半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为北京神 州细胞生物技术集团股份公司（以下简称"神州细胞"或"公司"或"上市公司"） 2021 年度向特定对象发行股票的保荐人，根据《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续督 导职责，并出具本持续督导半年度跟踪报告。 （4）对公司及其控股股东、实际控制人、董事、监事、高级管理人员进行 公开信息查询； （5）查询公司公告的各项承诺并核查承诺履行情况； 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2024 年 9 月 6 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审计等内部控制制度等文件 ...